Multicenter pahse II trial of neoadjuvant goserelin acetate and tamoxifen treatment for premenopausal ER-positive and HER2-negative breast cancers

Multicenter pahse II trial of neoadjuvant goserelin acetate and tamoxifen treatment for premenopausal ER-positive and HER2-negative breast cancers - ZTNeo trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006945

Enrollment

100

Registered

2011-12-26

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Premenopausal breast cancer

Interventions

Treatment with goserelin acetate (3.6mg, q4w) and tamoxifen (20mg/day) for 24 weeks.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed premenopausal breast cancer (female between 20 and 55 years old) 2. Stage I-III (TNM) 3. Estrogen receptor positive (positive cells were more than 10%) 4. HER 2 negative (IHC score 0, 1 or 2 and FISH-negative) 5. Containing measurable tumor 6. PS: 0-1 (ECOG) 7. Signed written informed consent

Exclusion criteria

Exclusion criteria: 1. Another cancer diagnosed within 5 years 2. Pregnant or nursing women 3. Cases who physician judged improper to entry this trial

Design outcomes

Primary

Measure	Time frame
clinical response rate	—

Secondary

Measure	Time frame
Pathological response, Rate of breast conserving surgery, safety, disease free survival	—

Countries

Japan

Contacts

Public ContactYasuo Miyoshi

Hyogo College of Medicine Department of Breast and Endocrine Surgery

ymiyoshi@hyo-med.ac.jp0798-45-6374

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026